Day: April 19, 2022

On 18 April 2022, the Supervisory Board of Nordic Fibreboard AS approved the company’s audited annual report for 2021. OVERVIEW OF OPERATING RESULTS Consolidated net sales for 2021 were € 10.10 million (2020: € 10.27 million). Fibreboard sales for year 2021 were € 9.84 million, a 2% decrease from year 2020 sales of € 10.00 million. Main reason for such decline was due to the closure of the Püssi fibreboard factory in March 2020 triggered by the COVID-19 pandemic, as a result of which production volume decreased. The sales revenue in 2021 from real estate management was € 254 thousand (2020: € 212 thousand), the increase in sales revenue was due to the addition of tenant to the production facilities. There was no sales from the furniture retail in 2021, as the company ceased its active economic activity already on 31.01.2020. In 2020...

TORONTO, April 19, 2022 (GLOBE NEWSWIRE) — Dundee Corporation (TSX: DC.A) (the “Corporation” or “Dundee”) today announces its wholly-owned subsidiary, Dundee Resources Limited (“Dundee Resources”), has entered into a binding Cooperation and Commitment Deed with Aura Minerals Inc. (TSX: ORA) (“Aura”) that will see Dundee Resources, a 19.3 percent shareholder in Big River Gold Limited (ASX: BRV) (“Big River”), retain a 20.0 percent interest in Big River through a joint venture arrangement with Aura, subject to certain conditions. In conjunction with this announcement, Aura unveils plans to acquire 100 percent of Big River. Transaction HighlightsAura to acquire 100 percent of Big River and form an 80/20 percent joint venture with Dundee Resources. Big River shareholders (other than Dundee Resources) to receive A$0.36 in cash consideration...

New agreement with the fastest-growing veterinary telehealth and pet-care marketplace provides 24/7 access to over 70,000 veterinarians for PetMeds®’ millions of pet parents. DELRAY BEACH, Fla., April 19, 2022 (GLOBE NEWSWIRE) — PetMed Express, Inc. (NASDAQ: PETS), Your Trusted Pet Health Expert, today announced an exclusive partnership and investment with Vetster Inc., a leading veterinary telemedicine and pet-care marketplace. The deal unlocks access to virtual, around-the-clock pet healthcare for PetMeds®’ 2 million-plus pet parents as well as integrated fulfillment of pet medications for veterinarians and vet clinics. The move further positions PetMeds as the premier source for pet health online.  Through the agreement — the first of its kind to enable pet telemedicine on a mass scale — PetMeds becomes the exclusive e-commerce...

Expects to Report Results of Independent Data Monitoring Committee (IDMC) Mandated Interim Safety Reviews and Interim Efficacy Review in the Second Half of 2022 SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States, today announced that the amended ENVASARC protocol approved by the U.S. Food and Drug Administration (“FDA”) in February has now been approved by institutional review boards or ethics committees at all 30 clinical sites: 29 in the United States and one in the United Kingdom. In February,...

Dr. El-Gabry’s extensive leadership experience will be critical to accelerating Akoya’s groundbreaking spatial biomarker research technologies into clinical tools that will impact patient careEhab A. El-Gabry Akoya appoints Ehab A. El-Gabry, MD as Chief Medical OfficerMARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company’s Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya’s strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company’s vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist...

Accomplished business executive and attorney with diverse industry experience including over 20 years in life sciences and pharma with successful track record in value-creating transactions, international business, strategic planning, and mergers and acquisitions of public and private companies EDMONTON, Alberta, April 19, 2022 (GLOBE NEWSWIRE) — Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of Geneviève Foster to its Board of Directors. Ms. Foster is an established businesswoman, attorney and corporate executive with a background in several industries including life sciences and pharma. Over the course of her career, she has negotiated...

Highlights include plans for $108 Million in Construction Projects, and Increases of over 28% in Sales and $8 Million in Assets FORKED RIVER, N.J., April 19, 2022 (GLOBE NEWSWIRE) — Dream Homes & Development Corporation (OTCPK: DREM)(also known as “DHDC”), announces it filed the Form 10-K annual report for the year ended December 31, 2021 and is now available at DREM 2021 Annual Report. New developments with signed letters of intent, as well as four developments owned by the Company, represent over $108 million in forecasted new home construction projects. This work is anticipated to occur over the next 3-4 years and is in addition to the elevation/renovation division of the business. Management is very positive about these new developments, as well as the cutting-edge construction technologies being employed to create healthier,...

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin®/ Macrilen™in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April 19, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that European Patent Office (EPO) has issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin®; Macrilen™) for use to diagnose growth hormone deficiency (GHD) in adults. Macimorelin, a ghrelin agonist, is an orally active...